ABSTRACT
The number and biomass of prey captured were estimated for Pinguicula alpina, P. villosa and P. vulgaris in a subarctic environment. Seasonal captures were estimated for one site per species for 4-5 years. Captures were related to reproductive status (reproductive/non-reproductive) and to leaf area. For one species (P. vulgaris) the catch was also compared across a range of habitats. Of the seasonal catch, 50-75% was obtained during June and less than 5% during August. For P. alpina and P. villosa the seasonal catch varied threefold or more between years (means of 89-329 µg dry matter plant-1 season-1 for P. alpina, and 11-91 µg dry matter plant-1 season-1 for P. villosa), whereas the between-year variation for P. vulgaris was small (mean c. 600 µg plant-1 season-1). Large variations were, however, observed among habitats for P. vulgaris. Captured prey may contribute a substantial amount of nutrients to the most successful individuals (up to 85% of the mean seasonal turnover), but prey capture varied greatly and during any given season many individuals obtained only marginal amounts of nutrients through carnivory. P. vulgaris trapped almost twice as much per unit leaf area and season as the other two species (224 for P. vulgaris versus 127 µg cm-2 season-1 for the other two species). Reproductive individuals of P. vulgaris trapped almost twice as much as non-reproductive individuals (after taking differences in leaf area into account). For the other two species no differences were observed between reproductive and non-reproductive individuals.
ABSTRACT
Two double-blind, double-dummy, randomized multicentre studies compared the safety and efficacy of 10-day regimens of cefaclor advanced formulation (cefaclor AF) (375 mg twice daily) with cefaclor (250 mg three times daily) in the treatment of proven group A beta-haemolytic streptococcal pharyngitis/tonsillitis. Of the 1,138 patients enrolled, 764 (cefaclor AF:392; cefaclor: 372) were evaluated for efficacy. All patients enrolled in the studies (570 treated with cefaclor AF and 568 treated with cefaclor) were evaluated for safety. Clinical and bacteriological evaluations were performed on treatment days 4-6, and after completion of treatment within 3-5 days and 2-3 weeks. In evaluable patients, the post-therapy clinical success and bacteriological cure rates for cefaclor AF were 96.7% and 93.6%, respectively; the rates were 98.1% and 94.1% for cefaclor. Sixteen cefaclor AF-treated patients and 14 cefaclor-treated patients withdrew early from the trial because of adverse events. There were no significant differences between treatment groups in the overall number of adverse events reported. Diarrhoea was the most frequently reported adverse event (5.6%) in cefaclor AF-treated patients, and headache/migraine was the most frequently reported adverse event (5.6%) in the cefaclor-treated patients. Cefaclor AF (375 mg twice daily) is as effective and safe as cefaclor capsules (250 mg three times daily) in the treatment of streptococcal pharyngitis/tonsillitis.
